Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 2,955 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $75.00, for a total value of $221,625.00. Following the transaction, the insider now directly owns 16,112 shares of the company’s stock, valued at $1,208,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Darin Lippoldt also recently made the following trade(s):

  • On Monday, December 4th, Darin Lippoldt sold 6,279 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.04, for a total value of $471,176.16.
  • On Wednesday, November 15th, Darin Lippoldt sold 9,900 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $73.05, for a total value of $723,195.00.

Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded up $1.25 during mid-day trading on Monday, reaching $73.75. The company had a trading volume of 873,500 shares, compared to its average volume of 1,101,527. Neurocrine Biosciences, Inc. has a 1-year low of $37.35 and a 1-year high of $75.98. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period last year, the company earned ($0.43) earnings per share. equities research analysts forecast that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current fiscal year.

Several research firms have recently commented on NBIX. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, November 14th. Robert W. Baird reaffirmed a “buy” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a report on Friday, November 3rd. BMO Capital Markets reaffirmed an “outperform” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 5th. Leerink Swann reaffirmed an “outperform” rating and set a $72.00 target price (up from $67.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 10th. Finally, Deutsche Bank reaffirmed a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $78.88.

A number of hedge funds have recently modified their holdings of the stock. Teacher Retirement System of Texas grew its holdings in Neurocrine Biosciences by 0.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock worth $320,000 after buying an additional 57 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the period. Utah Retirement Systems lifted its position in Neurocrine Biosciences by 1.9% in the second quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock worth $736,000 after purchasing an additional 300 shares during the period. Aperio Group LLC lifted its position in Neurocrine Biosciences by 3.7% in the second quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock worth $1,027,000 after purchasing an additional 789 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its position in Neurocrine Biosciences by 0.7% in the third quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock worth $7,380,000 after purchasing an additional 810 shares during the period.

TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Insider Sells $221,625.00 in Stock” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/11/neurocrine-biosciences-inc-nbix-insider-sells-221625-00-in-stock.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.